Biotech Values

[DewDiligence]

PFE inks MoU for branded generics in China:

http://finance.yahoo.com/news/Pfizer-and-Hisun-Sign-MOU-to-bw-624151727.html?x=0&.v=1

Pfizer Inc. and Zhejiang Hisun Pharmaceuticals, a leading pharmaceutical company in China, today jointly announced the signing of a memorandum of understanding (MOU) on their intention to establish a joint venture. This potential partnership would aim to strengthen the ability of both companies to reach more patients with high-quality and low-cost medicines in the branded generics arena.

As I’ve stated on numerous occasions (e.g. #msg-61960541), the future of the pharma industry lies in selling branded generics in emerging markets. By now I must sound like a broken record, but I will keep beating the drum because many investors still don’t get it.